mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition

Document Details

Document Type
Pub Defense Publication
Publication Date
Jan 01, 2021
Source ID
10.1074/jbc.ra120.014960

Entities

People

  • James F. Gusella
  • Justin T Jordan
  • Luke Witt
  • Roberta L. Beauchamp
  • Scott R. Plotkin
  • Serkan Erdin
  • Vijaya Ramesh

Organizations

  • National Institutes of Health
  • United States Army Medical Research and Development Command